Serge Saxonov - Feb 28, 2025 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Chief Executive Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov
Stock symbol
TXG
Transactions as of
Feb 28, 2025
Transactions value $
-$24,393
Form type
4
Date filed
3/4/2025, 06:50 PM
Previous filing
Feb 26, 2025
Next filing
Mar 19, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Sale -$84.4K -7.94K -0.9% $10.63 872K Feb 28, 2025 Direct F1, F2
transaction TXG Class A Common Stock Options Exercise $60K +50K +5.74% $1.20 922K Mar 4, 2025 Direct
holding TXG Class A Common Stock 27 Feb 28, 2025 See footnote F3
holding TXG Class A Common Stock 870 Feb 28, 2025 See footnote F4
holding TXG Class A Common Stock 213K Feb 28, 2025 See footnote F5
holding TXG Class A Common Stock 22.6K Feb 28, 2025 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -50K -74.11% $0.00 17.5K Mar 4, 2025 Class A Common Stock 50K $1.20 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on September 12, 2024 and terminated effective March 4, 2025.
F2 This transaction was executed in multiple trades at prices ranging from $10.415 to $10.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F4 The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
F5 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F6 The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
F7 This option, originally for 300,000 shares, of which 282,537 have been exercised, vested as to 1/48th of the shares on October 1, 2017, and was fully vested as of October 1, 2021.